Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dioxidine for Preventing Recurrence of Infection Stones After PCNL
NCT07393711Not yet recruiting
- Sponsor
- West Kazakhstan Marat Ospanov Medical University
- Start
- Mar 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of dioxidine in nephrolithiasis and urinary tract infection (UTI) (2 arms), sponsored by West Kazakhstan Marat Ospanov Medical University. Primary endpoint: Recurrence of infection-related kidney stones at 12 months. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
dioxidine
03
Conditions
nephrolithiasisurinary tract infection (UTI)
Beyond the preview
Go deeper on NCT07393711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07393711.